An In-Line Quarter, a Confident 2026 Preview, and an Upgrade on Deck: Maintaining Hold

Results vs. Consensus

Q3 2025 Scorecard

Year-Over-Year Comparison

Quarter-Over-Quarter Comparison

Quality of Beat

Revenue: The 7.5% ex-COVID organic growth is the number that matters, and it is squarely on Abbott's high-single-digit algorithm. Recently launched products generated nearly $5B in the quarter and added more than 100bp to organic growth, a useful gauge of pipeline productivity. The composition is again lopsided (Medical Devices up 12.5%, Diagnostics down 7.8% reported) but the device acceleration versus Q2 (12.2% → 12.5%) and the EPD strength (7.1% organic) show breadth where it counts. The $21M headline miss is immaterial.

Margins: This is where the quarter is softest and the most honest. Adjusted gross margin of 55.8% was down year-over-year, the first meaningful quarter of tariff impact, compounded by the seasonal Q3 plant-maintenance shutdowns. The CFO reiterated ~60bp of year-to-date gross-margin expansion and a ~57% go-forward profile, but the sequential 120bp step-down from Q2's 57.0% is a real watch item. Operating margin still expanded 40bp to 23.0% on SG&A leverage, so the bottom-line algorithm held, but the pace of margin expansion has slowed from the 100bp prints earlier in the year.

EPS: The $1.30 grew 7.4% on a reported basis and double digits once the large, telegraphed COVID-testing decline is removed. There is no financial engineering in the number, the gap to the $0.94 GAAP figure is intangible amortization, acquisition/restructuring, and tariff-related items consistent with the historical bridge. The EPS algorithm is intact; the question the margin line raises is how much tariff drag carries into 2026 before mitigation fully catches up.

Segment Performance

Medical Devices, The Engine Accelerates

Medical Devices accelerated to 12.5% organic, and the breadth deepened: Electrophysiology and Rhythm Management both stepped up into the mid-teens, joining Diabetes Care, Heart Failure, and Structural Heart in double-digit territory. The CRM story is the quiet standout, ten consecutive quarters outgrowing the market on the AVEIR leadless-pacemaker platform, which management says has moved CRM from flat five years ago to double-digit today, with single-chamber ~50% penetrated and dual-chamber still sub-10%. The strategic logic Ford laid out is the device thesis in one sentence: keep the high-growth franchises (diabetes, EP, structural heart) accelerating while repositioning the historically flat segments (CRM, Vascular) to mid-single-digit and then double-digit growth.

"If you look at our CRM business… it's gone from being flat to now being double digit. That has a tremendous [effect]… vascular is on the same journey that CRM was on, maybe a year or so behind… My expectation is [this is] very sustainable." — Robert Ford, Chairman & CEO

Assessment: The device engine is doing exactly what the bull case requires, and accelerating into it. The franchise-by-franchise reposition-the-laggards playbook is real and is the mechanism by which a 48%-of-revenue segment sustains double-digit growth at scale. This is the core of any constructive case on Abbott, and it strengthened this quarter.

Diagnostics, Ugly Headline, Forming Inflection

The reported Diagnostics decline of 6.6% (7.8% organic) is the worst-looking number in the release, and it is almost entirely Rapid Diagnostics, which fell 27.7% on the combination of the U.S. foreign-aid HIV-testing funding cut and the COVID-testing comp. Strip COVID out and the segment was roughly flat (+0.4%). The underlying story is more constructive than the headline: ex-China Core Lab grew 7%, U.S. Core Lab grew 10% on new-business capture as the Alinity platform takes share, and the European and Latin American regions grew mid-to-high single digit and mid-teens respectively. The China drag (the VBP price reset plus a DRG-driven volume effect) was in line with the prior two quarters, and Ford, fresh off a week in China meeting stakeholders, said he is beginning to see volume re-pick-up and expects the comp to start easing in Q4.

"We're starting to see a little bit now of some of that volume start to re-pick up… if you look at how that happened to us, it really started happening in Q4 of last year. So we'll start to see a little bit of that headwind comp start to be minimized in Q4… diagnostics is set up for a nice recovery year next year." — Robert Ford, Chairman & CEO

Assessment: This is the most important segment for the rating trajectory. The reported number is scary; the underlying ex-China, ex-COVID business is healthy and the U.S. is accelerating on share gains. We continue to treat China VBP as a durable repricing, but the combination of (a) the China comp easing from Q4, (b) the USAID/COVID drags lapping in 2026, and (c) U.S./international Core Lab acceleration sets up Diagnostics to swing from a drag to a low-to-mid-single-digit contributor next year. That swing is precisely the diagnostics inflection we said in Q2 we needed to see to get more constructive. It is forming, not yet confirmed.

Nutrition, Adult Strong, Pediatric Gives Back Share

Nutrition grew 4.0% organically to $2.15B, in line with its historical rate. Adult Nutrition (+5.4% organic) again led, with international up 10% on Ensure and Glucerna; Abbott launched a one-gram-sugar Glucerna and a 42-gram-protein Ensure to keep the brands current with consumer protein trends. U.S. Pediatric was the soft spot: Abbott gave back share it had captured during a 2024 competitor supply disruption and lost a large state WIC contract. Management expects a couple of soft Pediatric quarters but has already won two new WIC contracts (combined larger than the one lost) that take effect in Q1–Q2 2026.

Assessment: Nutrition remains the lower-growth, cash-generative ballast. The Pediatric share give-back is a known, temporary headwind with a visible recovery path through the new WIC wins and product launches, the same playbook that recovered share after 2022. Not a thesis factor either way.

Established Pharmaceuticals (EPD), Steady Compounder

EPD grew 7.1% organically to $1.51B, led by double-digit Key-15 emerging-market growth across gastroenterology, cardiometabolic, and pain management. The biosimilar build-out advanced with several regulatory approvals progressing and launches on the planned cadence that began this year.

Assessment: EPD is the reliable, demographics-driven mid-to-high-single-digit grower the market underrates, and the biosimilar optionality begins contributing in 2026. A quiet, durable support to the company algorithm.

Key Topics & Management Commentary

Overall Management Tone: Confident and forward-leaning, with a notably more assured posture on 2026 than the defensive crouch of the July call. Where Q2 was spent sizing and containing the diagnostics headwind, Q3 was spent describing how it laps and what replaces it, a heavy new-product cadence and accelerating device franchises. The tone shift is the story: management has moved from "absorbing headwinds" to "underwriting next year." The one area of candor was the gross-margin line, where the CFO openly acknowledged the first real tariff bite rather than papering over it.

1. The 2026 Setup: Three Buckets of Growth

Asked point-blank whether he remained comfortable with 2026 consensus (high-single-digit organic sales, double-digit EPS), Ford was unequivocally yes, and framed the durability around three buckets: underlying portfolio momentum (Libre, AVEIR, TAVR, TriClip), a heavy 2026 new-product launch cadence (Volt in the U.S., TactiFlex Duo, the dual-analyte sensor, Alinity N, biosimilars), and the easing of this year's $1B-plus diagnostics headwind as the China VBP and COVID/USAID comps lap.

"I'm very comfortable with consensus… these estimates… are pretty much in line with the results that we've delivered year to date. And we delivered those results in a year where we faced larger-than-expected headwinds in diagnostics and unexpected impact from tariff… no excuses, just adapt and deliver." — Robert Ford, Chairman & CEO

Assessment: This is the most important commentary for the forward thesis and the basis for our "upgrade on deck" framing. Ford is explicitly underwriting a clean 2026 in which the headwinds lap, the device franchises sustain, and a deep launch cadence layers on. The credibility is high, he made the same comfortable-with-consensus call at last year's Q3 and delivered through worse-than-expected headwinds. The formal 2026 guide at Q4 is the catalyst that converts this confidence into an upgradeable fact.

2. FreeStyle Libre: U.S. Noise, Structural Runway Intact

Diabetes Care reached $2.0B (+16.2% organic) with CGM up 17%. The one wrinkle was a U.S. growth rate of 19% that looked like a "slight miss" versus the first half, which Ford attributed to a first-half pull-forward from pharmacy/wholesaler restocking as Abbott's new manufacturing site came online faster than planned, not to demand. U.S. is on track for the original full-year 20%+ assumption (YTD +25%). He reiterated the long runway: basal is only ~20% penetrated in the U.S. and <5% internationally, the non-insulin segment is expanding, and the dual-analyte glucose-ketone sensor arrives in 2026 to drive intensive-insulin share.

"We remain on track with the original U.S. full-year growth assumption of over 20%. So demand is still very, very strong… there's still a lot of opportunity for growth in the U.S. with continued basal penetration." — Robert Ford, Chairman & CEO

Assessment: The U.S. deceleration is a restocking timing artifact, not a demand signal, and the structural runway (basal under-penetration, non-insulin TAM, dual-analyte differentiation, potential CMS type-2 non-insulin coverage that management notably is NOT baking into 2026) is fully intact. Libre remains the highest-quality asset in the portfolio. No thesis change; the crown jewel still shines.

3. Electrophysiology: The Volt PFA Rollout and a Full Portfolio

EP grew 13.7% organically with double-digit growth in the U.S. and internationally, and the European Volt PFA launch is going well, double-digit ablation-catheter growth internationally, with physician feedback emphasizing focused energy delivery (broader, deeper, more durable lesions; lower hemolysis risk) and the real-time contact visualization from the integrated mapping system, which reduces applications and enables conscious-sedation procedures. The U.S. Volt launch is targeted for mid-2026. Ford reframed Abbott's prior "playing defense" narrative as a "quiet offensive," using PFA adoption on competitive systems to expand its mapping capital footprint ahead of bringing its own catheter.

"It's increasingly clear to me that companies are going to need more than just PFA. You're going to need to have PFA and… LAA. And we've got both of those. So I don't think it's a question of Abbott being late. We're right on time, and we're complete with the full portfolio." — Robert Ford, Chairman & CEO

Assessment: The Volt European data and the full PFA-plus-LAA portfolio position Abbott to convert its installed mapping base into catheter share as the U.S. launch arrives in 2026. EP is a double-digit grower with a clear acceleration path; the "right on time, full portfolio" framing is credible given the mapping footprint. A key 2026 device catalyst.

4. Rhythm Management / AVEIR: A Genuine Standard-of-Care Shift

CRM grew 13.0%, AVEIR's tenth consecutive quarter outgrowing the market. Ford sized the low-voltage pacing market at ~$4B and laid out the penetration runway: single-chamber ~50% penetrated, dual-chamber sub-10%, both mostly U.S., with international (Europe, Japan) momentum building. He expects the outperformance to continue for at least two more years and aspires to make Abbott the leadless-pacing market leader.

Assessment: AVEIR is the cleanest example of Abbott's "reposition a flat franchise to double-digit" playbook working, and the penetration math (dual-chamber sub-10%) implies years of runway. An underappreciated compounding contributor inside the device story.

5. Structural Heart: A Number-Two Franchise Building Toward Mitral

Structural Heart grew 11.3% on TAVR share gains and TriClip adoption, with two milestones: TriClip's Japan approval (first minimally invasive tricuspid-regurgitation treatment there) and a CE Mark expanding Navitor TAVR to low/intermediate-risk patients (VANTAGE data). Ford framed Structural Heart as a number-two revenue position built on purpose, with multiple multi-year catalysts (Navitor/MitraClip label expansions, fifth-gen MitraClip/TriClip, geographic expansion, a bolt-on AI imaging acquisition for pre-procedure planning) and, most notably, a mitral-replacement program he has gotten personally close to.

"I've been closer to the mitral replacement program recently… the feedback… is just spectacular… it's got the potential to live up to the expectation that we all had back in 2015… that mitral could be as big as TAVR." — Robert Ford, Chairman & CEO

Assessment: Structural Heart is a durable double-digit grower with a genuine, large optionality in mitral replacement, a market that has been promised since 2015 and never delivered at scale. Ford's unusually emphatic personal endorsement of the program is a signal worth tracking. The pivotal trial enters the clinic in 2026.

6. Gross Margin and Tariffs: The First Real Bite

The CFO was direct that Q3 absorbed the first meaningful tariff impact in gross margin, compounded by the seasonal Q3 plant-maintenance shutdowns, producing the 120bp sequential step-down to 55.8% adjusted. He pointed to ~60bp of year-to-date gross-margin expansion, a dedicated tariff-mitigation team feeding ideas to the gross-margin-expansion teams, and a ~57% go-forward profile, with full-year tariff effects to be worked through in 2026.

"The first meaningful impact of tariffs that we're feeling in gross margin is in the third quarter… we are on track with year-to-date 60 basis points of gross margin expansion and comfortable that pattern will continue and maintain that 57% outlook in the profile going forward." — Philip Boudreau, CFO

Assessment: This is the clearest near-term risk in the model and the reason the rating holds rather than moves up today. Tariffs are now an active gross-margin drag, the full-year effect lands in 2026, and mitigation is a process rather than a switch. The operating-margin algorithm held on SG&A leverage, but the gross-margin trajectory is the one line where the "double-digit EPS with margin expansion" pillar is being tested. We want to see the ~57% profile defended into 2026.

7. The New-Product Engine: ~$5B and Building

Recently launched products generated nearly $5B in the quarter and contributed more than 100bp to organic growth, and management framed 2026 as a step-up in that contribution with a balanced mix of iterative and transformative launches: Volt U.S., TactiFlex Duo, the dual-analyte sensor, the next-gen Alinity N diagnostic system, and the emerging-market biosimilar portfolio. Abbott will run close to 200 clinical trials across its businesses in 2026, initiating pivotal trials for mitral-valve replacement, a balloon-expandable TAVR (IDE), AVEIR conduction-system pacing, a peripheral IVL (intravascular lithotripsy) IDE, and a continuous lactate-monitor sensor IDE.

Assessment: The pipeline productivity is the engine underneath the "sustain high-single-digit growth" claim. A $5B-per-quarter new-product contribution that is set to grow, plus a pivotal-trial slate that funds the 2027–2029 growth, is exactly what a durable compounder needs to show. This is a genuine bull pillar and it is well-supported.

8. China: Sized, Contained, De-emphasized

Asked about China holistically, Ford noted it is now <6% of total Abbott revenue (down from ~9–10% a decade ago), with EPD and Nutrition up double digits year-to-date and cardio/neuro stepping up sequentially. Ex-Diagnostics, China is growing 5–7%; the diagnostics VBP piece is the lone large drag, with the Q3 decline in line with Q1–Q2. He targets mid-single-digit normalized China growth for 2026 and is placing more emphasis on other geographies.

Assessment: China is a contained, declining-mix exposure rather than a swing factor. The VBP drag is the one large negative and it is lapping; the rest of China is healthy. The candid mid-single-digit framing (versus a peer's mid-teens claim Ford gently dismissed) is the right kind of conservatism.

9. NEC Litigation: Two Federal Summary-Judgment Wins

On the preterm-infant-formula NEC litigation, Ford declined case-specific comment but flagged a material development: over the prior couple of months, Abbott won summary judgment in both of the recent federal cases. He drew a distinction between how the federal cases are being adjudicated versus some earlier state cases, and reaffirmed Abbott's commitment to defending the product.

"In both those [federal] cases, Abbott won on summary judgment… there's clearly a difference in terms of how the federal cases are being looked at versus… some of those earlier state cases." — Robert Ford, Chairman & CEO

Assessment: A genuine improvement to the bear case. The two federal summary-judgment wins do not eliminate the overhang (the state-court venue produced the headline adverse verdicts that created the risk) but a favorable federal-court trend meaningfully lowers the tail. The litigation remains unquantifiable, but the trajectory this quarter was positive.

10. Capital Allocation: Already Deploying, M&A Capacity Intact

Pressed on the balance sheet, Ford pushed back on the idea Abbott is sitting on cash: it is growing the dividend, buying back stock, paying down debt ($3B due next year), and investing internally (manufacturing, digital). On M&A, the posture is unchanged, a strong organic pipeline allows selectivity, but there are strategically-fitting opportunities that can generate attractive returns, and Abbott has the capacity. The quarter included a bolt-on: an AI-powered interventional-cardiology imaging/pre-procedure-planning software company in Europe.

Assessment: Disciplined, multi-pronged capital deployment with real M&A firepower held in reserve. The bolt-on imaging acquisition is a sensible tuck-in for Structural Heart. A larger, accretive deal remains a potential 2026 catalyst and an open swing factor.

Guidance & Outlook

The guide moved the right direction: the full-year adjusted EPS range narrowed up to $5.12–$5.18 (bottom raised $0.02, midpoint held at $5.15), and the organic-growth framework was reaffirmed. After Q2's $0.05 ceiling trim, a narrow-up is a modest but real positive, the second-half de-risking has held, not deteriorated further.

Implied Q4 ramp: With nine-month adjusted EPS of $3.65 ($1.09 + $1.26 + $1.30) and a $5.15 full-year midpoint, Q4 is implied at ~$1.50, the seasonal high, supported by a favorable ~1.5% FX tailwind on Q4 sales, the new-product cadence, and the beginning of the diagnostics comp easing.

2026 framing: The more important guidance is qualitative: management is "very comfortable" with the high-single-digit-sales / double-digit-EPS consensus (~$5.60–$5.65 adjusted EPS), built on portfolio momentum, the 2026 launch cadence, and the headwind lap. The formal 2026 guide arrives with Q4 results in January, and it is the single most important catalyst for our rating.

Guidance style: Consistent with Abbott's conservative, land-at-or-above-midpoint track record. The narrow-up plus the firm 2026 endorsement read as confidence, not stretch.

Analyst Q&A Highlights

Whether Management Is Still Comfortable With 2026 Consensus

The opening question went straight at the forward setup, asking whether management remained comfortable with the Street's 2026 sales and EPS, given the tailwinds building. The answer was an emphatic yes, anchored to a track record of making and delivering the same call a year earlier through worse-than-expected headwinds.

Q: "Back in July, you sounded comfortable with consensus sales and EPS for 2026. I'd love to hear your high-level thoughts on next year — if you're still comfortable with consensus, it seems like you have some nice tailwinds next year."
— Larry Biegelsen, Wells Fargo

A: "I'm very comfortable with consensus… this is a question that was asked last year in our Q3 call and consensus for 2025 at that time was… seven and a half percent [sales], EPS growth of [double digits]. That's the same consensus we have today… I'm comfortable again today forecasting to deliver that type of growth next year."
— Robert Ford, Chairman & CEO

Assessment: This is the exchange the forward rating hinges on. Management is underwriting a clean 2026 and explicitly invoking its track record of delivering the same forecast through adversity. We take it as credible, and it is why an upgrade is on deck, but the rating moves on the formal January guide, not on the endorsement.

The Diagnostics Recovery Path and the Underlying Drivers

A question pressed on the underlying Diagnostics drivers and whether the segment can accelerate going forward as the China VBP, DRG, USAID, and COVID headwinds moderate into 2026. Management's answer separated the lapping China comp from the accelerating ex-China business and pointed to U.S. share gains as the swing factor.

Q: "Could you maybe talk a little bit more on some of the underlying drivers of the [diagnostics] business and how you think about an overall acceleration… going forward?"
— David Roman, Goldman Sachs

A: "We're starting to see… volume start to re-pick up [in China]… we'll start to see a little bit of that headwind comp start to be minimized in Q4… U.S. has done incredibly well… up 10% this quarter… I think diagnostics is set up for a nice recovery year next year."
— Robert Ford, Chairman & CEO

Assessment: The most decision-relevant exchange for the diagnostics inflection. The combination of a lapping China comp and a 10%-growing U.S. business is the mechanism that turns Diagnostics from a drag to a contributor in 2026. It is forming on schedule; confirmation comes when the reported segment line turns positive.

FreeStyle Libre: U.S. Trajectory and the Ketone Sensor

A question probed the U.S. Libre dynamics (a beat driven by international with a slight U.S. softening) and how the dual-analyte ketone sensor and potential CMS type-2 non-insulin coverage shape the outlook. Management attributed the U.S. optics to a first-half restocking pull-forward and reaffirmed the 20%+ full-year U.S. assumption and the multi-segment runway.

Q: "Beat overall driven by outside the U.S. with the slight miss in the U.S.… how you're thinking about the market developing, particularly in the U.S. with the ketone sensor on its way… and what seems like increasing commentary on CMS coverage of non-intensive type 2?"
— Robbie Marcus, JPMorgan

A: "U.S. grew 19%… year-to-date the U.S. is up 25%… growth in the first half was a little higher really due to some shelf restocking dynamics… we remain on track with the original U.S. full-year growth assumption of over 20%… I'm not building [CMS type-2] into my base forecast for 2026."
— Robert Ford, Chairman & CEO

Assessment: The U.S. softness is a timing artifact, not a demand crack, and management notably is NOT counting on CMS type-2 non-insulin coverage in 2026, meaning any such decision is upside, not base case. Both points are constructive for the Libre pillar.

The Sustainability of Double-Digit Device Growth

A big-picture question asked how Abbott sustains 10-plus quarters of double-digit device growth given underlying procedure-market growth. Ford's answer was the clearest articulation of the device strategy: keep the high-growth franchises accelerating while repositioning the historically flat segments to mid-single-digit and then double-digit growth.

Q: "You've had kind of 10-plus quarters of double-digit growth. Just trying to think about the sustainability of that going forward when you think about… the underlying procedure market growth and the pipeline."
— Travis Steed, BofA Securities

A: "How do we reposition what we would characterize as historically slower-growth segments… from being flat to at least growing mid single digits[?]… If you look at our CRM business… it's gone from being flat to now being double digit… vascular is on the same journey… My expectation is [this is] very sustainable."
— Robert Ford, Chairman & CEO

Assessment: This is the mechanism behind the device pillar, and it is repeatable, CRM proved it, Vascular is mid-journey. A 48%-of-revenue segment compounding at double digits because management systematically converts its laggards is a structurally stronger story than a single hot product. Strengthens Bull-3.

Gross Margin: Decomposing Tariffs, FX, and Operations

A P&L question asked management to decompose the gross-margin line into tariff, FX, and operational pieces and to frame the go-forward trajectory. The CFO confirmed Q3 as the first meaningful tariff quarter, layered on the seasonal plant-maintenance shutdowns, and pointed to year-to-date expansion and a defended ~57% profile.

Q: "In the gross margin line, there are probably a lot of moving parts… the first quarter burdening the impact of tariffs and then also probably some foreign exchange… can you help us decompose the operational performance from those other factors[?]"
— David Roman, Goldman Sachs

A: "The first meaningful impact of tariffs that we're feeling in gross margin is in the third quarter… we are on track with year-to-date 60 basis points of gross margin expansion and comfortable that pattern will continue and… maintain that 57% outlook in the profile going forward."
— Philip Boudreau, CFO

Assessment: Honest and useful. The tariff bite is real and lands fully in 2026, and the ~57% gross-margin profile is now a "show-me." This is the line that keeps the rating at Hold rather than letting the device acceleration pull it up today.

Nutrition Softness and the NEC Litigation

A two-part question asked about pockets of Nutrition softness and the status of the NEC litigation. Management attributed the Pediatric softness to a temporary U.S. share give-back plus a lost WIC contract (with recovery already contracted), and flagged the two federal NEC summary-judgment wins.

Q: "Could you give us an update on where we're sitting on the NEC litigation? Then it looks like there were some pockets of nutrition that were weaker this quarter than we would have expected…"
— Joanne Wuensch, Citi

A: "In both those [federal] cases, Abbott won on summary judgment… [on Pediatric] we gave back some share that we had captured last year when a competitor experienced a supply disruption… we recently won two new WIC contracts… higher than the one that we lost… [effective] Q1 and Q2 of next year."
— Robert Ford, Chairman & CEO

Assessment: Both halves are constructive. The Pediatric softness is a known, temporary, already-being-recovered share issue, and the two federal NEC wins lower the litigation tail. The bear case eased on both fronts this quarter.

What They're NOT Saying

1. A formal 2026 number: Management is "very comfortable" with consensus but declined to give its own 2026 framework, standard for an October call, but it means the actual upgrade-relevant guide is still three months away. Endorsing consensus is cheaper than owning a guide.
2. How much tariff drag carries into 2026: The CFO confirmed the first meaningful tariff quarter and a full-year 2026 effect, but did not quantify the 2026 gross-margin headwind or the pace at which mitigation offsets it. The ~57% profile is asserted, not bridged.
3. A China VBP recovery magnitude: Ford sees volume "starting to re-pick up" but again declined to size the recovery or commit to a China diagnostics growth rate, the same vagueness as Q2 on the single most durable piece of the drag.
4. Dual-analyte sensor and Volt U.S. timing specifics: Both are "2026" with no firm dates; the most important device catalysts remain un-dateable from the outside.
5. The size of the NEC liability: Two federal wins were volunteered, but no reserve level, settlement framework, or remaining-case exposure, the overhang is improving but still unquantified.

Market Reaction

• Pre-print setup: ABT closed at $133.27 on October 14, up 17.8% YTD (versus the S&P 500's +13.0%) and +14.8% over the trailing twelve months, near the upper end of its $111.10–$140.22 52-week closing range. The stock had recovered the entire Q2 air pocket (from the $120.51 July low) and then some.
• Reaction-day move (October 15, BMO report): Shares gapped down 3.9% at the open ($128.01), traded a $125.74–$131.48 range, and closed at $129.45, down 2.9% ($3.82).
• Volume: 14.9M shares versus a 5.6M 30-day average, a 2.7x spike, elevated but far below Q2's 4.9x; a normal-sized reaction, not a repositioning panic.
• Index backdrop: The S&P 500 rose 0.4% on the session, so the 2.9% decline was idiosyncratic.

A 2.9% pullback on an in-line print, off a YTD high, is a textbook mild sell-the-news. Two specifics did the work: the optically-ugly Diagnostics reported decline (−6.6%), which a headline-reading tape penalized before parsing the ex-China/ex-COVID strength underneath, and the tariff-driven gross-margin step-down, which complicates the clean "margin expansion every quarter" narrative. Neither is a thesis-breaker; both are reasons for a stock at ~23x to give back a couple of points rather than rip on a meet. The far-milder reaction versus Q2 (2.9% vs. 8.5%) is itself a signal that expectations had been reset to a more reasonable level entering this print.

Street Perspective

Debate: Is the Diagnostics Inflection Real, and Does It Arrive in 2026?

Bull view: The reported decline is all Rapid Diagnostics (USAID/COVID), which laps in 2026. Underneath, ex-China Core Lab grew 7%, U.S. grew 10% on Alinity share gains, and China volume is beginning to recover with the comp easing from Q4. Diagnostics swings from a ~$1B drag to a low-to-mid-single-digit contributor next year, adding 100bp-plus to company growth.

Bear view: China VBP is a permanent repricing, USAID funding may not return, and "starting to see volume re-pick up" is the same hedged language as last quarter. The segment could stay sub-trend longer than management implies, and a diagnostics business that needs a comp tailwind to look healthy is structurally low-growth.

Our take: Bull on direction, cautious on magnitude. The inflection is forming (the math of a lapping comp plus accelerating ex-China is hard to argue with) but we treat China VBP as a durable repricing and want to see the reported segment line actually turn positive before crediting it. This is the gating item for our upgrade.

Debate: Do Tariffs Break the Margin-Expansion Pillar?

Bull view: Operating margin still expanded 40bp despite the first tariff quarter, year-to-date gross margin is up ~60bp, and Abbott has a multi-year track record of gross-margin-expansion teams offsetting cost pressure. The ~57% profile holds, mitigation compounds, and the double-digit-EPS-with-margin-expansion algorithm survives 2026.

Bear view: Q3 gross margin was down year-over-year, the full tariff effect lands in 2026, and mitigation is a multi-quarter process. If the ~57% profile slips, the EPS algorithm leans entirely on revenue and SG&A leverage, and the "margin expansion every year" part of the story stalls just as the multiple needs it.

Our take: Lean bull but watch closely. Abbott's mitigation track record is real, but the 2026 gross-margin trajectory is the single most important thing to verify on the January call. This is why we hold rather than upgrade today.

Debate: Valuation, Is ~23x Forward Fair After the Recovery?

Bull view: At $129.45 and ~$5.65 2026 EPS, Abbott trades at ~22.9x forward, reasonable for a high-single-digit organic grower with double-digit EPS, an accelerating device engine, a deep launch cadence, and headwinds about to lap. As Diagnostics inflects in 2026, estimates move up and the multiple re-rates.

Bear view: ~23x forward is full for a 7–8% organic grower, especially with the Q2 drop already recovered, tariffs pressuring margins, and an unquantified (if improving) NEC overhang. The easy money from the July reset is gone; from here you are paying up for an inflection that has not been confirmed.

Our take: The bear has the near-term edge on valuation; the bull has the better 12-month setup. At ~23x with the upgrade catalyst (the 2026 guide) one quarter away, the risk/reward is balanced. We hold, with a base-case 12-month target of ~$140 (~24.8x our $5.65 forward estimate), a bull case near $155 (27.5x if 2026 re-accelerates and Diagnostics inflects cleanly), and a bear case near $115 (~20x if tariffs bite harder or the diagnostics recovery slips). Base-case upside of ~8% keeps this a Hold, for now.

Model & Valuation Framework

Valuation framework: At $129.45, Abbott trades at ~25.1x the $5.15 FY2025 midpoint and ~22.9x the ~$5.65 2026 consensus. The device acceleration and the forming diagnostics inflection justify nudging our base-case target to ~$140 (24.8x forward), but that still implies only ~8% upside, broadly in line with our expected market return. The 12-month setup is improving faster than the price, which is exactly the configuration that puts an upgrade on deck without yet justifying one.

What would move us to Outperform (the watch list for Q4): a formal 2026 guide that confirms high-single-digit organic growth and double-digit EPS with the diagnostics headwind demonstrably lapping; the reported Diagnostics line turning positive; and a defended ~57% gross-margin profile despite the full-year tariff effect. What would move us to Underperform: a 2026 guide below the algorithm, evidence the China VBP recovery has stalled, a material adverse NEC development reversing the federal trend, or a gross-margin profile that slips meaningfully below 57%.

Thesis Scorecard Post-Earnings

We score this quarter against the standing thesis established at our July initiation. The commitments we set to watch were: the China Core Lab volume recovery, Diagnostics returning toward flat-to-positive ex-COVID, the FY2025 EPS guide holding or narrowing up, Libre holding high-teens, Medical Devices holding double-digit, and any 2026 framing or M&A. The scorecard:

Overall: The thesis strengthened. Three of four bull pillars are confirmed or strengthened (the device engine accelerated and the reposition-the-laggards playbook is proven), Bear-1 (diagnostics) is easing toward an inflection, and Bear-2 (NEC) improved on two federal wins. The two pillars that argue for patience are Bull-4/Bear-4 (tariffs now actively pressure gross margin, with the full effect in 2026) and Bear-3, valuation, which recovered to ~23x. The net is a clearly improving setup that has not yet cleared the two specific gates (a confirmed diagnostics inflection and a defended margin profile, both of which the January 2026 guide addresses) for an upgrade.

Action: Maintain Hold. The thesis is moving our way and an upgrade is on deck for Q4. We hold here on an in-line print, an active tariff drag, and a full multiple, and we will move to Outperform when the 2026 guide confirms the re-acceleration.

Bottom Line: Improving Into an Upgrade Window

Rating decision: We maintain Hold on Abbott. Q3 was the quarter the thesis began to turn: the device engine accelerated rather than fatigued, management firmed its 2026 endorsement from "reasonable" to "very comfortable," the EPS guide narrowed up after Q2's trim, the diagnostics inflection started forming under an ugly headline, and the NEC litigation produced two federal wins. Almost everything we said in July we needed to see, we are starting to see.

What we have not yet seen is the confirmation that justifies paying up: a formal 2026 guide, a reported Diagnostics line that turns positive, and a gross-margin profile defended against the full-year tariff effect. All three are January events. The stock, meanwhile, has recovered the entire Q2 drop and trades at ~23x forward, so the price is no longer doing the work for us. This is the textbook "maintain into a catalyst", the setup is better, the rating action waits for the proof.

What we are watching into Q4 / FY2025 (January 2026):